INTRODUCTION
============

Asthma is a chronic immunological disorder of the lung characterized by reversible airway obstruction, airway inflammation, and increased airway hyperresponsiveness in response to provocative challenge. It is a complex disease that involves the interplay between multiple physiological processes.[@B1] Physiological changes of the disease include accumulation of inflammatory cells, especially eosinophils, and goblet cell metaplasia of lung epithelium with a mucus-secreting phenotype.[@B2] To reduce the disease burden of asthma, it is critical to understand its genetic and environmental risk factors. It is well known that the genetic background for asthma susceptibility is strong, with estimates of heritability up to 75%.[@B3] Genome-wide linkage and genome-wide association (GWA) studies have found that more than 100 genes are associated with the development of asthma and asthma-related phenotypes.[@B4] Several studies showed that variation in 17q12-21 locus harboring ORM1-like 3 (*ORMDL3*) and gasdermin B (*GSDMB*) is associated with asthma. *ORMDL3* is a gene encoding ORM1-like 3, a transmembrane protein of the endoplasmatic reticulum, and a member of the family of orosomucoid-like proteins, which is produced in a number of cells, including lymphocytes and liver cells. *ORM* proteins regulate sphingolipid production, and altered expression of *ORM* genes or mutations affecting their phosphorylation sites can result in deregulation of sphingolipid production.[@B5] *ORMDL3* is also involved in the development of the unfolded protein response, a process that can initiate inflammation, which may explain the reported association between *ORMDL3* with asthma.[@B6] Multiple SNPs within the *ORMDL3* gene, including rs8076131 and rs12603332, have been reported to be associated with asthma in different populations.[@B7],[@B8],[@B9],[@B10] In a study by Galanter et al.[@B8] African Americans and Mexicans showed a positive association between rs12603332 and asthma, and Puerto Ricans showed a negative association. Contradictory results had also been reported for rs3744246 polymorphism of *ORMDL3*.[@B7],[@B11] Moffatt et al.[@B12] genotyped healthy children and patients with childhood-onset asthma from Germany and the UK. In their study, German subjects showed a positive association of rs3744246 and asthma while UK subjects showed a negative association.

*GSDMB* encodes gasdermin B, a member of the family of gasdermin domain containing proteins. These proteins participate in numerous cell processes which are associated with tumor growth and progression, such as cell differentiation, cell cycle control, and apoptosis.[@B13] The role of gasdermin B in bronchial asthma (BA) is still not clear, but it is known that gasdermin B participates in terminal differentiation of epithelial cells.[@B14] *GSDMB* may also have a role in stem cell proliferation.[@B15] Studies showed both positive and negative associations between rs7216389 of *GSDMB* and asthma.[@B7],[@B12],[@B16],[@B17],[@B18],[@B19],[@B20],[@B21] In the study by Galanter et al.,[@B8] Puerto Ricans showed a positive association of rs7216389 and asthma, while African Americans and Mexicans showed a negative association. The Costa Rican Hispanic subjects showed a positive association of rs7216389 and asthma and the Non-Hispanic White subjects from the Childhood Asthma Management Program (CAMP) showed a negative association in the study of Verlaan et al.[@B22]

These conflicting results about the association of *GSDMB* and *ORMDL3* gene polymorphisms with asthma raised the question regarding the significance of these SNPs in asthma pathogenesis. Obviously, the statistical power of an individual study could be very limited for the efficient assessment of these variants. Integration of these datasets may provide improved statistical power to detect the significance. The transmission/disequilibrium test (TDT) based on family is particularly advantageous with less confounding caused by population admixture and has the same importance as case-control study in genetic association analysis.[@B23] Therefore, we have electronically searched all genetic association studies published in the field of asthma and *GSDMB* or *ORMDL3* and conducted a meta-analysis of published studies to integrate the results from both case-control and TDT studies to provide more precise evaluation for the association of rs8076131, rs12603332, and rs3744246 of *ORMDL3* and rs7216389 of *GSDMB* with susceptibility of asthma.

MATERIALS AND METHODS
=====================

Study identification and data extraction
----------------------------------------

We searched the PubMed biomedical database (US National Library of Medicine, Bethesda, Maryland) for all English-language articles related to asthma and *GSDMB* and *ORMDL3* genetic polymorphisms that had been published through January 24, 2014.

We used the following search criterion: \'*GSDMB*\' or \'gasdermin B\', \'*ORMDL3*\' or \'ORM1-like 3\' in combination with \'asthma\'. Eligible studies fulfilled the following inclusion criteria: (1) either case-control or TDT study design; (2) data on either or both of *GSDMB* and *ORMDL3* polymorphisms; (3) presentation of data necessary for calculating odds ratios (ORs); and (4) studies including either children or adult (\>18-year-old) patients with clear definition of asthma. Case reports, editorials, nonepidemiologic studies (*e.g.* studies on animals or cell culture), treatment outcome studies and review articles were excluded. The full texts of the candidate articles were examined to determine whether they contained sufficient information on the *GSDMB* or *ORMDL3* gene polymorphism and asthma. Furthermore, reference lists were also reviewed to trace further relevant studies. In total 17 studies (13 case-control studies and 4 TDT studies) with 6,691 asthma subjects and 9,281 healthy controls, and 1,360 nuclear families were included in this review.

The following data were extracted using a piloted data extraction form: name of the first author, year of publication, ethnicity, type of study design, and diagnostic criteria for asthma. Information about the counts of alleles in case and control groups in case-control studies and numbers of transmitted alleles from heterozygous parents to affected offspring in family-based studies was also extracted.

Statistical analysis
--------------------

We estimated unadjusted odds ratios (OR) for published genotype frequencies. The associations were indicated as pooled odds ratios with corresponding 95% confidence intervals. For meta-analysis, the overall or pooled estimate of risk was obtained by using the Mantel-Haenszel method in the fixed effects model[@B24] or by the DerSimonian and Laird method in the random effect model.[@B25] In the absence of heterogeneity, the random-effects and fixed-effects models will provide similar results. We assessed the within- and between-study variation or heterogeneity by testing Cochran\'s Q-statistic.[@B26] This heterogeneity test assessed the null hypothesis that all studies were evaluating the same effect. When a significant Q-statistic (*P*\<0.10) indicated heterogeneity across studies, the random effect model was used for meta-analysis to take into account the possibility of heterogeneity between studies. Otherwise, the fixed effects model was used. Fixed effects model assumes all of the studies are estimating the same underlying effect and considers only within-study variation. As studies in this review were from different populations and heterogeneity was inherent, we chose to use random effect model first. However, in the meta-analyses of rs3744246 and rs8076131, the fixed effects model was used given the fact that tau2 was less than or equal to 0 and no random effect estimates could be calculated.

We used funnel plot and Egger\'s test to detect publication bias. A funnel plot is a useful graph designed to check the existence of publication bias in meta-analyses. Publication bias can be visualized with a funnel plot which is a scatter plot of sample size and effect size. We also evaluated publication bias using Egger\'s linear regression test,[@B27] which measures funnel plot asymmetry on the natural logarithm scale of the odds ratio. The Chi-square goodness of fit test was used to test if observed frequencies of genotypes in controls conformed to Hardy-Weinberg (HWE) expectations.

For the synthesis of case-control and TDT studies, the method described by Kazeem et al.[@B28] was used. After obtaining the estimate of logarithm of the OR and its associated SE in each case-control or TDT study, the estimate of combined OR and its associated SE can be calculated by a weighted analysis method. The Catmap software implemented this method for the fix-effects model and extended this method for the random-effects model of DerSimonian and Laird to conduct case-control and TDT meta-analysis, which could be downloaded from the comprehensive R network (<http://www.r-project.org>).[@B29] Additionally, sensitivity analysis was performed to assess the influence of each study on the overall estimate. Cumulative meta-analysis was also conducted via the assortment of studies by publication time. All P values were 2-tailed with a significant level at 0.05. All statistical analyses were carried out in Catmap software V1.6.

RESULTS
=======

Studies included in the meta-analysis
-------------------------------------

An initial screening of all abstracts produced 24 articles containing information on either *GSDMB* or *ORMDL3* polymorphisms and asthma. Eligible studies were genotype-based case-control studies and TDT studies that reported associations of rs8076131, rs12603332, and rs3744246 of *ORMDL3* and rs7216389 of GSDMB polymorphisms with asthma. Both hospital-based and population-based studies were included in the analysis. Eleven studies were excluded because they did not provide the data necessary for calculating odds ratios or they did not provide the data of the 4 SNPs of this review.[@B30],[@B31],[@B32],[@B33],[@B34],[@B35],[@B36],[@B37],[@B38],[@B39],[@B40] According to the prespecified inclusion criteria, in total 13 reports[@B7],[@B8],[@B9],[@B10],[@B11],[@B12],[@B16],[@B17],[@B18],[@B19],[@B20],[@B21],[@B22] were included in this review, including 17 studies (13 case-control studies and 4 TDT studies) with 6,691 subjects with asthma and 9,281 controls. Most of the studies were about childhood asthma (12 childhood asthma studies, 4 adult asthma studies, and 1 study with both childhood and adult asthma subjects).

These 17 studies had been carried out in various countries, including China, Scotland, Russia, Korea, the United Kingdom, Germany, Australia, Canada, Costa Rica, Japan, the USA, Portugal, Hungary, Greece, Slovakia, and Czech Republic. A description of these studies is given in [Table 1](#T1){ref-type="table"}. The selected papers assessed the association of *GSDMB* and *ORMDL3* gene polymorphisms with asthma. Of these papers, 3[@B7],[@B8],[@B9] evaluated the association of the rs8076131 polymorphism with asthma risk; 4[@B7],[@B8],[@B9],[@B10] the association of the rs12603332 polymorphism with asthma, 4[@B7],[@B8],[@B11],[@B12] the association of the rs3744246 polymorphism with asthma, and 11[@B7],[@B8],[@B11],[@B12],[@B16],[@B17],[@B18],[@B19],[@B20],[@B21],[@B22] the association of the rs7216389 polymorphism with asthma.

Combining results of case-control and TDT studies
-------------------------------------------------

Meta-analyses for *GSDMB* and *ORMDL3* were conducted using 4 SNPs in 20,052 participants. Three SNPs (rs8076131, rs12603332, and rs3744246) of *ORMDL3* and 1 SNP (rs7216389) of *GSDMB* were all associated with asthma at the *P*\<0.05 level ([Figs. 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). For the most significant marker, rs7216389 of *GSDMB*, the T allele was consistently less common in controls than in asthma cases. Random effects (DerSimonian-Laird) pooled odds ratio was 1.37 (95% confidence intervals (CIs), 1.27-1.47), with evidence of heterogeneity (χ^2^=40.04, *P*\<0.01). We subsequently obtained results for associations of rs8076131 and rs3744246 of *ORMDL3* with asthma. The A allele of rs8076131 was significantly higher in asthma cases compared to controls (OR=1.10; 95% CIs, 1.02-1.20) by the fixed effects model. The random-effects model (DerSimonian-Laird) showed apparent evidence of association between the C allele of rs12603332 and asthma (OR=1.15; 95% CIs, 1.05-1.25). The odds ratio of the C allele of rs3744246 for asthma was 1.10 (95% CIs, 1.02-1.17) by the fixed effects model.

Stratified analysis
-------------------

Stratified analysis was performed by the type of study design for rs7216389 of *GSDMB*. In case-control studies, evidence of between-study heterogeneity was not found for rs7216389 of *GSDMB* (χ^2^=14.74, *P*~heterogeneity~=0.14). The pooled allelic OR in the random-effects model was 1.44 (95% CI, 1.35-1.53, *P*\<0.01). In TDT studies, the heterogeneity test showed positive results (χ^2^=8.50, *P*~heterogeneity~=0.04). In the random-effects model, this variant was associated with asthma risk (OR=1.20; 95% CIs, 1.05-1.37; *P*=0.007) ([Table 2](#T2){ref-type="table"}). In the stratified analysis by age at onset of the disease, 12 studies[@B7],[@B11],[@B12],[@B16],[@B17],[@B18],[@B19],[@B20],[@B21] provided age at onset of the disease subgroup information, and significant associations between rs7216389 polymorphism and asthma risk were found for both the subgroup of adults (OR=1.50; 95% CIs, 1.38-1.63) and the subgroup of children (OR=1.38; 95% CIs, 1.02-1.87). Because there were less than 3 studies of the subgroup of TDT or adults for rs8076131, rs12603332, and rs3744246 of *ORMDL3* in this review, we did not perform stratified analysis.

Sensitivity analyses for combined studies of GSDMB and ORMDL3 polymorphism
--------------------------------------------------------------------------

Given the significant between-study heterogeneity for *GSDMB* rs7216389 polymorphism, we conducted a sensitive meta-analysis to assess the effect of each individual study on the combined OR. A random-effects model was employed since heterogeneity was indicated. A series of combined OR with 95% CIs produced repeatedly after the removal of each individual study was greater than 1.0, suggesting the stability of the outcome that rs7216389 was associated with asthma risk ([Table 4](#T4){ref-type="table"}). Additionally, sensitivity analyses indicated that all studies contributed to the heterogeneity for rs7216389 equally. The *P* values for the Q test were all not less than 0.1 after deletion of each individual study, and the effect of rs7216389 was steadily significant.

Cumulative meta-analysis
------------------------

Cumulative meta-analyses of these 4 variants were also conducted via assortment of studies in chronological order. [Figs. 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"} showed the results from the cumulative meta-analyses for rs7216389 and rs12603332 in the random-effects model and rs8076131 and rs3744246 in the fixed effects model. Rs3744246 and rs8076131 both tended to have no significant association over time, and rs7216389 and rs12603332 tended to have significant associations over time. Moreover, with increasing data the 95% CIs became increasingly narrower, suggesting that the precision of the estimates was progressively enhanced by continually adding more studies.

Publication bias
----------------

We assessed potential publication bias by examining funnel plots and using Egger\'s test. Egger\'s test detects whether the intercept deviates significantly from zero in a regression of the standardized effect estimates against their precision. The sensitivity of the regression method is generally low in meta-analysis based on less than 20 trials.[@B41] There was no publication bias for rs8076131, rs7216389, and rs12603332 (*P*=0.106, 0.289, and 0.591, respectively). The result of Egger\'s test of rs3744246 was significant (*P*=0.011). We neglected publication bias because the small number of studies was included in this review.

DISCUSSION
==========

This current meta-analysis, to the best of our knowledge, is the first study to integrate the case-control and TDT studies to reflect the precision effect of *GSDMB* and *ORMDL3* variants in asthma risk. Our meta-analysis showed that moderate evidence existed for associations of the *ORMDL3* rs8076131, rs12603332 and rs3744246 and *GSDMB* rs7216389 variants with asthma.

In the past few years, precise definition of asthma phenotypes has become increasingly important in the study of the genetic architecture and disease triggers of these phenotypes. Based on twin studies, estimates of the heritability of asthma ranged between 75%[@B42] and 92%.[@B43] Advances in technology have allowed genome-wide association studies to replace candidate gene studies and the susceptibility locus for asthma was identified[@B12],[@B22],[@B44] as 17q12-21.1, which contained the *GSDMB* and *ORMDL3* genes. 17q12-21 polymorphisms were found to be associated with the presence and severity of asthma across different populations. The gasdermin gene was originally identified as a candidate gene responsible for the phenotype of a mouse skin mutant, namely recombination-induced mutation 3 (Rim3).[@B45] *GSDMB* is expressed as an oncogene product in stem cell-resident regions of normal epithelium.[@B46] *ORMDL3* is the third member of the gene family that encodes trans-membrane proteins that are anchored in the endoplasmic reticulum.[@B47] *ORMDL3* binds and inhibits the sarcoendoplasmic reticulum Ca^2+^ pump, resulting in a reduced ER Ca^2+^ concentration and an increased unfolded-protein response, which is relevant in chronic inflammatory diseases, such as asthma.[@B6] Although the present knowledge of the *ORMDL3* function is limited, a study in yeast has shown that the gene product may be involved in protein folding.[@B6] Studies of *ORMDL3* in Puerto Rican asthmatics have demonstrated a significant association between SNP rs12603332 and IgE levels,[@B8] whereas subgroup analysis showed important associations between SNPs rs4378650 and rs12603332 in patients with allergic asthma (IgE \>100 IU/mL). Associations between these SNPs and asthma became stronger in patients with IgE level \>100 IU/mL.[@B8] Although the function of *GSDMB* is not clear, the polymorphisms of *GSDMB* and *ORMDL3* which are located in 17q gene were associated with early-onset asthma, smoking exposure,[@B44] and several asthma-related phenotypes, including IgE[@B11] and change in FEV1 in response to albuterol.[@B8]

Tavendale et al.[@B16] confirmed that the rs7216389 C/T polymorphism at locus 17q21 controlling *ORMDL3* gene expression was strongly associated with the occurrence of childhood asthma, which showed that the effect was dose-dependent with each C to T substitution at the SNP site, and the odds of the occurrence of asthma was increased by about 50%, with the homozygous T allele being associated with doubled odds of the homozygous C allele. In addition to its effects on asthma susceptibility, the study from Tavendale et al.[@B16] also showed that the rs7216389 polymorphism was associated with the risk of asthma exacerbations.

The rs12603332 (C allele) and rs8076131 (A allele) of *ORMDL3* are both in the intronic region. The rs12603332 SNP lies in a highly conserved element across species with a high correlation to the consensus target sequence for the transcription factor E47.[@B48],[@B49] E47, a member of the \"E protein\" family, a subset of helix-loop-helix proteins, has been linked to T- and B-cell development,[@B50],[@B51] and the C allele substitution in the position of rs12603332 reduces the transcription factor score of this region. Hrdlickova et al.[@B9] reported that high-risk allele A of rs8076131 is significantly associated with hypersensitivity to pollen, and also reported a marginal significant relationship between polymorphism rs8076131 and hypersensitivity to birch antigen. Genetic variant rs3744246 of *ORMDL3* was also significantly associated with allergic rhinitis in the Japanese population.[@B52] The expression level of the *ORMDL3* transcript was significantly correlated with the genotype of rs3744246, and ORMDL3 mRNA was highly expressed in nasal epithelium.

ORMDL3 is expressed in multiple cell types important to the pathogenesis of asthma (*i.e.*, epithelial cells, macrophages, eosinophils, and T cells),[@B53],[@B54] and increased expression of ORMDL3 in multiple cell types contributes to the pathogenesis of asthma. Recent work has suggested that ORMDL3 may play a role in viral respiratory infections.[@B21] A study by Miller et al.[@B55] showed that ORMDL3 plays an important role in the activation of the ATF6 UPR pathway *in vivo* and that expression of ORMDL3 *in vivo* regulates airway remodeling (smooth muscle, fibrosis, and mucus). In addition, the ORM protein is believed to be critical mediators of sphingolipid homeostasis that may contribute to the development of childhood asthma.[@B5] The human GSDM family consists of GSDMA, GSDMB, GSDMC, and GSDMD. The *GSDMA* and *GSDMB* genes are located at 17q21.2, and the *GSDMC* and *GSDMD* genes are located at 8q24.[@B13] *GSDMB* was revealed to have several polymorphisms associated with asthma susceptibility and asthma related phenotypes.[@B8],[@B11],[@B12],[@B16],[@B21],[@B31],[@B37],[@B40],[@B44] Among the genes, *GSDMB* and *ORMDL3* have received the most attention, and their genotype-mediated expression is also affected by rhinovirus infection, one of the most common and powerful triggers for asthma exacerbations.[@B56] Rs7216389 in *GSDMB* located in an intron was also strongly associated in cis with transcript levels of *ORMDL3* in EBV-transformed lymphoblastoid cell lines from children with asthma.[@B12] It has further been suggested that these 2 genes might be co-regulated, as their transcript levels seem connected.[@B22] The study of Bouzigon et al.[@B44] also showed an interaction between 17q21 variants and exposure to environmental tobacco smoke in early life. Among the offspring, an association between early-onset asthma and 11 SNPs (including rs7219923 of *GSDML* \[or *GSDMB*\] and rs8076131 of *ORMDL3*) was highly significant in the smoke-exposed families. Under the best-fitting recessive model, the overall risk of early-onset asthma when smoke exposure was not taken into account was increased for subjects who were homozygous for the risk alleles, as compared to those with other genotypes. However, exposure to environmental tobacco smoke in early life is associated with an even greater risk. Moreover, for SNPs showing significant heterogeneity, the SNP effect on early-onset asthma was significant in subjects with early exposure, as compared to those who did not have such exposure.

Our results confirm the role of the *ORMDL3* and *GSDMB* genomic area as a locus conferring susceptibility to asthma. In combination with the recent published studies in ethnically diverse populations, it highlights the importance of *ORMDL3* and *GSDMB* from the chromosome 17q21 region in the development of this complex disease. Despite the heterogeneity in biological function, further studies to examine the functions of *GSDMB* and *ORMDL3* should focus on their role in asthma pathogenesis because of strong correlations observed between SNPs in these genes and asthma in many different ethnic groups.

Asthma is a complex condition with several contributing pathologic processes. Genetic variation in these processes and individual variation in response to pharmacologic therapies combine to form the range of phenotypes seen in the condition. It is likely that deep resequencing of portions of *ORMDL3* and *GSDMB* will be necessary to uncover untypical or novel variants that contribute to associations between these genes and asthma. Asthma has very variable clinical subphenotypes, and genetic differences may explain the high heterogeneity of disease manifestations. Therefore, we encourage larger studies being conducted in this area. Larger, more comprehensive studies would make meaningful stratification possible, and would also permit evaluation of gene-gene and gene-environment interactions, and factors that are clearly important in complex diseases, such as asthma.
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###### Characteristics of studies included in a meta-analysis of ORMDL3 and GSDMB polymorphisms, and asthma
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  First author, year (Reference No.)   Country (ethnicity)   Sample size (cases/controls or family)   Design type        Gene     Polymorphisms evaluated   Risk allele   OR (95% CI)/χ^2^ (*P* value)   Genotype and method   P^HWE^ control
  ------------------------------------ --------------------- ---------------------------------------- ------------------ -------- ------------------------- ------------- ------------------------------ --------------------- ----------------
  Tavendale R, 2008^16^                Scotland (E)          1,279/1,541                              Case-control       GSDMB    rs7216389                 T             1.46 (1.31-1.62)               TaqMan                \>0.05
  Yang FF, 2012^7^                     China (Asia)          152/190                                  Case-control       GSDMB    rs7216389                 T             1.653 (1.170-2.333)            PCR                   \>0.001
  Yang FF, 2012^7^                     China (Asia)          152/190                                  Case-control       ORMDL3   rs8076131                 A             1.2 (0.843-1.708)              PCR                   \>0.001
  Yang FF, 2012^7^                     China (Asia)          152/190                                  Case-control       ORMDL3   rs12603332                C             1.2 (0.843-1.708)              PCR                   \>0.001
  Yang FF, 2012^7^                     China (Asia)          152/190                                  Case-control       ORMDL3   rs3744246                 C             1.243 (0.868-1.779)            PCR                   \>0.001
  Karunas AS, 2011^17^                 Russia (E)            358/369                                  Case-control       GSDMB    rs7216389                 T             1.8 (1.45-2.23)                Illumina              NS
  Russians                                                                                                                                                                                                                     
  Tatars                                                                                                                                                                                                                       
  Bashkirs                                                                                                                                                                                                                     
  Hrdlickova B, 2011^9^                Czech Republic (E)    337/331                                  Case-control       ORMDL3   rs12603332                C             1.118 (0.902-1.387)            TaqMan                \>0.05
  Hrdlickova B, 2011^9^                Czech Republic (E)    337/331                                  Case-control       ORMDL3   rs8076131                 A             1.077 (0.866-1.338)            TaqMan                \>0.05
  Yu J, 2011^18^                       Korea (Asia)          786/522                                  Case-control       GSDMB    rs7216389                 T             1.264 (1.055-1.514)            PCR                   \>0.05
  Galanter J (A), 2008^8^              America (AA)          261/176                                  Case-control       GSDMB    rs7216389                 T             1.21 (0.79-1.93)               PCR                   NS
  ORMDL3                               rs8076131             A                                        1.20 (0.76-1.90)   PCR      NS                                                                                           
  ORMDL3                               rs12603332            C                                        1.74 (1.24-2.44)   PCR      NS                                                                                           
  ORMDL3                               rs3744246             C                                        1.40 (0.96-2.04)   PCR      NS                                                                                           
  Moffatt MF (G), 2007^12^             German (E)            728/694                                  Case-control       GSDMB    rs7216389                 T             1.475 (1.272-1.710)            Illumina              NS
  Moffatt MF (G), 2007^12^             German (E)            728/694                                  Case-control       ORMDL3   rs3744246                 C             1.222 (1.01-1.479)             Illumina              NS
  Moffatt MF (B), 2007^12^             British (E)           306/1,041                                Case-control       GSDMB    rs7216389                 T             1.634 (1.359-1.965)            Illumina              NS
  Moffatt MF (B), 2007^12^             British (E)           306/1,041                                Case-control       ORMDL3   rs3744246                 C             1.246 (0.986-1.576)            Illumina              NS
  Li FX, 2012^10^                      China (Asia)          241/212                                  Case-control       ORMDL3   rs12603332                C             1.217 (0.903-1.641)            Sequenom MassARRAY    \>0.05
  iPLEX platform                                                                                                                                                                                                               
  Binia AD, 2011^19^                   UK (E)                397/1,429                                Case-control       GSDMB    rs7216389                 T             1.42 (1.21-1.67)               TaqMan                \>0.05
  Leung TF, 2009^11^                   China (Asia)          315/192                                  Case-control       GSDMB    rs7216389                 T             1.231 (0.905-1.675)            PCR                   \>0.05
  Leung TF, 2009^11^                   China (Asia)          315/192                                  Case-control       GSDMB    rs3744246                 C             1.191 (0.874-1.622)            PCR                   \>0.05
  Ferreira MA, 2011^20^                Australia (E)         986/1,846                                Case-control       GSDMB    rs7216389                 T             1.25 (1.12-1.40)               Illumina              NS
  Hirota T, 2008^21^                   Japan (Asia)          545/738                                  Case-control       GSDMB    rs7216389                 T             1.44 (1.2-1.73)                TaqMan                NS
  Verlaan DJ (CR), 2009^22^            Costa Rica (LA)       382                                      Family             GSDMB    rs7216389                 T             19.6 (9.32×3^10^-6^^)          TaqMan                NS
  Verlaan DJ (CA), 2009^22^            CAMP (NA)             278                                      Family             GSDMB    rs7216389                 T             2.24 (0.130)                   TaqMan                NS
  Galanter J (P), 2008^8^              Puerto Ricans (LA)    399                                      Family             GSDMB    rs7216389                 T             1.35 (1.07-1.70)               PCR                   NS
  Galanter J (P), 2008^8^              Puerto Ricans (LA)    399                                      Family             ORMDL3   rs8076131                 A             1.29 (1.03-1.62)               PCR                   NS
  Galanter J (P), 2008^8^              Puerto Ricans ( LA)   399                                      Family             ORMDL3   rs12603332                C             1.22 (0.98-1.52)               PCR                   NS
  Galanter J (P), 2008^8^              Puerto Ricans ( LA)   399                                      Family             ORMDL3   rs3744246                 C             1.10 (0.86-1.41)               PCR                   NS
  Galanter J (M), 2008^8^              Mexican (NA)          301                                      Family             GSDMB    rs7216389                 T             1.26 (0.95-1.65)               PCR                   NS
  Galanter J (M), 2008^8^              Mexican (NA)          301                                      Family             ORMDL3   rs8076131                 A             1.38 (1.05-1.81)               PCR                   NS
  Galanter J (M), 2008^8^              Mexican (NA)          301                                      Family             ORMDL3   rs12603332                C             1.36 (1.04-1.78)               PCR                   NS
  Galanter J (M), 2008^8^              Mexican (NA)          301                                      Family             ORMDL3   rs3744246                 C             1.35 (1.01-1.81)               PCR                   NS

OR, Odds ratio; 95% CI, 95% confidence intervals; A, America; G, German; B, British; CR, Costa Rica; CA, CAMP; P, Puerto Ricans; M, Mexican; E, European; AA, African American; EA, European American; SA, South American; NA, North America; LA, Latin America; *P*^HWE^, *P* value for Hardy-Weinberg equilibrium test; NS, not stated.

###### Random-effects odds ratios for asthma and heterogeneity test results for the risk allele of *GSDMB* (rs7216389) gene polymorphisms in relation to asthma

![](aair-7-175-i002)

  Study ID                Case-control   TDT           OR (95% CI)                                  
  ----------------------- -------------- ------------- ------------- ------- ---------------------- ---------------------
  Tavendale R, 2008       1,429/1,129    1,431/1,651                         1.46 (1.31-1.62)       
  Yang FF, 2012           237/67         259/121                             1.65 (1.16-2.34)       
  Karunas AS, 2011        426/290        332/406                             1.80 (1.46-2.21)       
  Yu J, 2011              1,216/356      762/282                             1.26 (1.06-1.51)       
  Galanter J (A), 2008    437/85         276/76                              1.42 (1.00-2.00)       
  Moffatt MF (G), 2007    830/626        657/731                             1.48 (1.27-1.71)       
  Moffatt MF (B), 2007    378/234        657/731                             1.63 (1.36-1.96)       
  Binia AD, 2011          432/338        1,352/1,506                         1.42 (1.21-1.67)       
  Leung TF, 2009          506/124        295/89                              1.23 (0.90-1.67)       
  Ferreira MA, 2011       1,045/927      1,735/1,957                         1.27 (1.14-1.42)       
  Hirota T, 2008          852/238        1,052/424                           1.44 (1.20-1.73)       
  Verlaan DJ (CR), 2009                                299           200                            1.50 (1.25-1.79)
  Verlaan DJ (CA), 2009                                202           173                            1.17 (0.95-1.43)
  Galanter J (P), 2008                                 533           474                            1.12 (0.99-1.27)
  Galanter J (M), 2008                                 441           403                            1.09 (0.96-1.25)
  Total                   7,788/4,414    9,186/8,290   1,475         1,250   1.44 (1.35-1.53)^\*^   1.20 (1.05-1.37)^†^
  Total                                                                      1.37 (1.27-1.47)^‡^    

^\*^Random-effects pooled OR, *P*\<0.01; χ^2^=119.58, Pheterogeneity=0.142; ^†^Random-effects pooled OR, *P*\<0.01; χ^2^=7.38, Pheterogeneity=0.037; ^‡^Random-effects pooled OR of case-control and TDT studies, *P*\<0.01; χ^2^=119.58, Pheterogeneity=0.142.

A, America; G, German; B, British; CR, Costa Rica; CA, CAMP; P, Puerto Ricans; M, Mexican.

###### Odds ratios for asthma and heterogeneity test results for the risk allele of ORMDL3 (rs3744246, rs12603332, rs8076131) gene polymorphisms in relation to asthma

![](aair-7-175-i003)

  Study ID               Case-control   TDT         OR (95% CIs)                                 
  ---------------------- -------------- ----------- -------------- ------ ---------------------- ------------------
  rs3744246                                                                                      
  Yang FF, 2012          239/65         284/96                            1.24 (0.87-1.78)       
  Galanter J (A), 2008   383/139        244/108                           1.22 (0.91-1.64)       
  Moffatt MF (G), 2007   1,213/243      1,115/273                         1.22 (1.01-1.48)       
  Moffatt MF (B), 2007   506/106        1,651/431                         1.25 (0.99-1.58)       
  Leung TF, 2009         502/126        291/87                            1.19 (0.87-1.62)       
  Galanter J (P), 2008                              592            583                           1.02 (0.91-1.14)
  Galanter J (M), 2008                              494            470                           1.05 (0.93-1.19)
  Total                  2,843/679      3,585/995   1086           1053   1.10 (1.02-1.17)^\*^   
  rs12603332                                                                                     
  Yang FF, 2012          235/69         281/99                            1.22 (0.85-1.75)       
  Galanter J (A), 2008   239/283        125/227                           1.53 (1.16-2.03)       
  Hrdlickova B, 2011     372/302        347/315                           1.12 (0.90-1.39)       
  Li FX, 2012            350/116        295/119                           1.22 (0.90-1.64)       
  Galanter J (P), 2008                              428            394                           1.09 (0.95-1.25)
  Galanter J (M), 2008                              430            391                           1.10 (0.96-1.26)
  Total                                                                   1.15 (1.05-1.25)^†^    
  rs8076131                                                                                      
  Yang FF, 2012          235/69         281/99                            1.20 (0.84-1.71)       
  Galanter J (A), 2008   176/454        68/289                            1.46 (1.00-2.11)       
  Hrdlickova B, 2011     397/277        378/284                           1.08 (0.87-1.34)       
  Galanter J (P), 2008                              535            490                           1.09 (0.97-1.23)
  Galanter J (M), 2008                              461            426                           1.08 (0.95-1.23)
  Total                  1,616/800      727/672     996            916    1.10 (1.02-1.20)^‡^    

^\*^Fixed-effects pooled OR, *P*=0.008; χ^2^=6.85, Pheterogeneity=0.45; ^†^Random-effects pooled OR, *P*=0.002;χ^2^=9.94, Pheterogeneity=0.36; ^‡^Fixed-effects pooled OR, *P*=0.012; χ^2^=6.22, Pheterogeneity=0.65.

A, America; G, German; B, British; P, Puerto Ricans; M, Mexican.

###### Sensitivity analysis of pooled OR combining family-based and case-control studies for *GSDMB* rs7216389 polymorphism

![](aair-7-175-i004)

  Study omitted           OR (95% CIs)       χ^2^    *P*^\*^   *P*^†^~heterogeneity~
  ----------------------- ------------------ ------- --------- -----------------------
  Tavendale R, 2008       1.36 (1.25-1.47)   54.72   \<0.01    \<0.01
  Yang FF, 2012           1.36 (1.26-1.47)   61.83   \<0.01    \<0.01
  Karunas AS, 2011        1.34 (1.25-1.44)   64.91   \<0.01    \<0.01
  Yu J, 2011              1.38 (1.27-1.49)   61.36   \<0.01    \<0.01
  Galanter J (A), 2008    1.37 (1.26-1.48)   62.04   \<0.01    \<0.01
  Moffatt MF (G), 2007    1.36 (1.25-1.47)   56.69   \<0.01    \<0.01
  Moffatt MF (B), 2007    1.35 (1.25-1.45)   60.29   \<0.01    \<0.01
  Binia AD, 2011          1.36 (1.26-1.48)   57.07   \<0.01    \<0.01
  Leung TF, 2009          1.37 (1.27-1.48)   64.06   \<0.01    \<0.01
  Ferreira MA, 2011       1.38 (1.27-1.50)   57.84   \<0.01    \<0.01
  Hirota T, 2008          1.36 (1.26-1.47)   57.97   \<0.01    \<0.01
  Verlaan DJ (CR), 2009   1.36 (1.26-1.47)   57.92   \<0.01    \<0.01
  Verlaan DJ (CA), 2009   1.38 (1.28-1.49)   66.35   \<0.01    \<0.01
  Galanter J (P), 2008    1.39 (1.29-1.50)   78.57   \<0.01    \<0.01
  Galanter J (M), 2008    1.39 (1.30-1.50)   82.63   \<0.01    \<0.01

^\*^DerSimonian and Laird random-effects model used to determine the significance of the overall OR; ^†^Cochran\'s χ^2^-based Q statistic test used to assess the heterogeneity.

TDT, transmission/disequilibrium test; A, America; G, German; B, British; CR, Costa Rica; CA, CAMP; P, Puerto Ricans; M, Mexican.

[^1]: Chun-Ni Zhao and Ye Fan contributed equally on this work.
